GLOBAL WHOLEHEALTH PTNRS - GWHP STOCK NEWS

Global WholeHealth Partners Corp. (OTC: GWHP) has gained approval to distribute its FDA-approved diagnostic tests through Amazon's Seller Marketplace, which has an estimated audience of over 300 million active users. This move could significantly enhance visibility and sales potential for their range of over-the-counter tests, including pregnancy and drug tests. CEO Charles Strongo stated this partnership could become a major distribution channel. The drug testing market alone is projected to be worth almost $12 billion by 2028, indicating strong growth potential for GWHP in this sector.

Global WholeHealth Partners Corp. (OTC: GWHP) has secured approval to sell its FDA-approved diagnostic tests through eBay's $100 billion online marketplace. With 180 million active buyers, this partnership presents a significant opportunity for visibility and potential revenue growth.

CEO Charles Strongo emphasized the lucrative prospects of reaching a vast audience. The Drug Testing Market is projected to reach $11.7 billion by 2028, while the Pregnancy Testing Market may grow to $1.74 billion by 2026, indicating solid demand for GWHP's products.

Global WholeHealth Partners Corp (OTC: GWHP) announced a collaboration with Nunzia Pharmaceutical to provide vaccines against COVID-19, specifically targeting the Delta variant, to governments at competitive prices. The vaccines have proven effective in minimizing infections and hospitalizations among the unvaccinated. The company is also preparing to launch Saliva Antibody IgG and IgM tests. GWHP has 56 FDA-approved products, including various COVID-19 tests, as they continue to expand their offerings amidst the ongoing pandemic, which has seen over 200 million global cases.

Global WholeHealth Partners Corp (OTC:GWHP) is introducing five OTC products targeting retail sales, including Pregnancy, Ovulation, Drug Tests, Glucose, and Colorectal Cancer Tests. With a strategic focus on leveraging increased online traffic, particularly on Walmart.com, which saw visits surge to 385.5 million in September 2020, the company is poised for expansion. Backed by an EMC2 agreement, GWHP can direct purchases up to $100 million over 36 months, supporting its growth initiatives. The firm holds 70 FDA-approved products, enhancing its market position.

Global WholeHealth Partners Corp (OTC: GWHP) has secured funding for growth and expansion through a new agreement with EMC2. The deal allows EMC2 to purchase up to $100 million in shares over 36 months, with a total of 8,578,177 shares available. The company specializes in cutting-edge in-vitro diagnostic tests, holding 70 FDA-approved products, including tests for SARS-CoV-2. The focus will be on retailing 5 OTC products while navigating various market risks and competition in the medical device industry.

Global WholeHealth Partners Corp. (OTC: GWHP) emphasizes its extensive range of Covid-19 testing solutions, including IgG/IgM and Antigen tests capable of detecting various SARS-CoV-2 variants. With rising Covid-19 cases in the U.S. and the emergence of new variants, the company is committed to advancing its research and development efforts. They currently offer 56 FDA-approved products for rapid diagnostic testing, utilizing cutting-edge technology to enhance public health safety. Their aim is to support rapid screening efforts as the demand for efficient testing grows amidst ongoing challenges posed by the pandemic.

Findit, Inc. (OTC PINK:FDIT) has announced the recognition of three members enhancing their online presence through Findit's marketing services. Featured members include American Craftsman Renovations, a general contractor in Savannah focusing on remodeling and handyman services; Global WholeHealth Partners (OTC PINK:GWHP), a provider of medical-grade PPE and rapid COVID-19 tests; and OTC Tip Reporter, which aids companies in increasing exposure via investor relations packages. Each member utilizes Findit's content creation and social media strategies to improve visibility.

Global WholeHealth Partners Corp (OTC:GWHP) announced a partnership with Salud Previa to sell 500,000 COVID-19 tests, including antigen and antibody tests capable of detecting the Delta variant. The company offers one of the largest lines of COVID-19 tests and holds FDA approvals for 56 products, with many available for over-the-counter use. Global WholeHealth emphasizes the need for faster testing and results to combat the ongoing pandemic.